Abstract:Rationale: To ensure that quality medicines are available to the populace. Aim and objective: To provide a new perspective for drug sampling and testing using a risk-based approach globally, and provide a reference for improving the efficiency of the drug sampling and testing programme in China. Method: This study used a combination of theoretical analysis and problem analysis. First, we analysed the high-risk drugs that should be given attention to theoretically in the drug sampling testing programme based on the healthcare reform in China. Second, this study leveraged on data on the sampling and testing of drugs extracted from self-constructed data by the China Food and Drug Administration (CFDA). The integrated and structured data sets were used to conduct an innovative analysis that identifies the actual content of the drug sampling and testing programme and contrasts them with the theoretical content to understand the problems. This study used quantitative and qualitative approaches for data analysis. Results: Following analysis, we discovered that there is still a big gap between the reality of drug sampling and testing in China and the ideal state of the objective requirements of healthcare reforms. The major sources of risk are the retail pharmacies or hospital pharmacies in the distribution chain of drugs; however, the CFDA sampled mostly drugs from drug manufacturers. Additionally, the CFDA did not sample adequate essential medicines, bid-winning drugs (especially those with large price drops in centralized procurement), biological products and other high-risk drug varieties. The high-risk drugs produced by companies or enterprises with a history of noncompliance, especially bid-winning enterprises in centralized procurement, were not sampled. Conclusion: We suggest that the major content of drug sampling and testing in China should focus on the link of drug utilization, varieties of drugs with large price drops in centralized procurement and bid-winning enterprises with a history of noncompliance.

Comparative Analysis of Drug Management Law in China with Related Laws and Regulations in America about the Definition of Counterfeit and Inferior Drugs and Its Enlightenment

Comparison on Definitions of Counterfeit or Substandard Drugs in Several Countries throughout the World

Analysis of the "regulation of Drug Price Difference (trial Implementation)" in China

Comparison and Analysis of the Health Products Supervisions in China,Japan,USA and EU

Comparison of the Retail Drug Prices between China and Other Developed Countries or Districts

On the Amendments of China’s Provisions for Drug Registration

Evaluation on administration off-label drug use at home and abroad

Study on Enterprise Strategies for the Evaluation of Quality and Efficacy Consistency of Generic Drugs

Analysis and Comparison of Foreign and Domestic Orphan Drug Registration Policies

Comparative analysis of consistency evaluation for generic drugs in foreign countries

Analysis of Related Literatures of New Drug Introduction Management in Medical Institutions in China

Analysis of provincial centralized bidding and procurement of drugs in China

Data Analysis and Comparative Study on Drug Recall in China And America

Analysis of the problems of drug sampling and testing programme under tripartite system reform in China

A comparative analysis of centralized drug procurement in China

Interpretation of the Drug Post-marketing Intensive Surveillance Policy in China

Analysis of Current Pharmaceutical Advertising Market in China

Study on Narcotics and Psychotropic Substances Control( Part Ⅴ):Comparative Study on Domestic and Foreign Control System of Narcotics and Psychotropic Substances

Analysis of Medicine-related Issues in New "patent Law"

Solving Patent Problem in the Registration and Approval of Drugs

On the Concept of Inexpensive Drugs